MARBOCYL BOLUS 50 MG TABLET
Ülke: İrlanda
Dil: İngilizce
Kaynak: HPRA (Health Products Regulatory Authority)
Ürün özellikleri
(SPC)
04-11-2016
Bu ürün için bazı belgeler şu anda mevcut değil, müşteri hizmetlerimize bir istek gönderebilirsiniz ve bunları alır almaz size bildireceğiz.
İstek gönder.
İstek gönder.
Aktif bileşen:
MARBOFLOXACIN
Mevcut itibaren:
Vetoquinol Ireland Limited
ATC kodu:
QJ01MA93
INN (International Adı):
MARBOFLOXACIN
Doz:
50 Milligram
Farmasötik formu:
Bolus
Reçete türü:
POM
Terapötik grubu:
Bovine
Terapötik alanı:
Marbofloxacin
Terapötik endikasyonlar:
Antibacterial
Yetkilendirme durumu:
Authorised
Yetkilendirme tarihi:
1999-08-23
Ürün özellikleri
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbocyl Bolus 50 mg Tablet
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
Off white bolus shaped convex tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (neonatal calves).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Marbocyl bolus is indicated in the treatment of neonatal gastroenteritis caused by _Escherichia coli_, in calves of 25-50 kg.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not exceed the recommended duration of treatment (3 days)
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
50.00 mg
For a full list of excipients, see section 6.1
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 19/10/2016_
_CRN 7023455_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
When administration is carried out using an applicator, care should be taken to avoid soft tissue injury.
Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be
reserved for the treatment of clinical conditions which have responded poorly, to other classes of antimicrobials.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating
from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may
decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
People with known hypersensitivity to fluoroquinolone
Belgenin tamamını okuyun
